Battah Mohammed Mohammed, Zainal Hadzliana, Ibrahim Doa'a Anwar, Md Hanafiah Nur Hafzan, Syed Sulaiman Syed Azhar
Department of Clinical Pharmacy and Pharmacy Practice, University of Science and Technology, Sana'a, Yemen.
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Blood Lymphat Cancer. 2025 Sep 4;15:149-166. doi: 10.2147/BLCTT.S538606. eCollection 2025.
Drug-related problems (DRPs) are critical challenges in oncology practice, particularly among patients with non-Hodgkin lymphoma (NHL), due to complex regimens and high toxicity potential.
This study aimed to identify, classify, and evaluate the prevalence of DRPs and associated factors, and explore the pattern of chemotherapy prescribing for NHL patients.
A cross-sectional study was conducted from November 2022 to September 2023 at National Oncology Centre (NOC), Al-Jomhouri Teaching Hospital. Adult NHL patients undergoing chemotherapy were enrolled, with a final sample of 279 patients. DRPs were identified and classified using the validated Pharmaceutical Care Network Europe (PCNE) and cross-checked against National Comprehensive Cancer Network (NCCN) guidelines. Potential drug-drug interactions (DDIs) were evaluated using the Lexicomp drug interactions database. Data was collected from patients' interviews, treatment charts and medical records. Descriptive statistics and linear regression were used for analysis.
Among the 279 NHL patients included in the study, a total of 1870 DRPs were identified (average 6.7 per patient). Advanced-stage disease was observed in 79.6% of patients, and 63.4% received rituximab-containing regimens. The R-CHOP regimen being the most frequently used, which was associated with 52.7% of all DRPs. The most frequent DRPs involved dosing issues, including drug doses too low (26.5%) and incorrect or missing dose calculations (13.1%). DDIs contributed to 13% of the total identified DRPs, with the majority classified as mild interaction. Multivariate regression analysis identified comorbidities, lymphoma subtype, and number of chemotherapy cycles as significant predictors of DRP occurrence.
A high number of DRPs were identified among NHL patients in Yemen, with an average of 6.7 DRPs per patient, predominantly due to dosing issues. Integration of clinical pharmacy services, guideline-based prescribing, and systematic medication reviews are essential to minimize DRPs and improve treatment outcomes.
由于治疗方案复杂且潜在毒性高，药物相关问题（DRPs）是肿瘤学实践中的关键挑战，在非霍奇金淋巴瘤（NHL）患者中尤为突出。
本研究旨在识别、分类和评估DRPs的患病率及相关因素，并探索NHL患者化疗处方模式。
2022年11月至2023年9月在Al-Jomhouri教学医院国家肿瘤中心（NOC）进行了一项横断面研究。纳入接受化疗的成年NHL患者，最终样本为279例患者。使用经过验证的欧洲药学保健网络（PCNE）识别和分类DRPs，并对照美国国立综合癌症网络（NCCN）指南进行交叉核对。使用Lexicomp药物相互作用数据库评估潜在的药物相互作用（DDIs）。数据从患者访谈、治疗图表和病历中收集。采用描述性统计和线性回归进行分析。
在纳入研究的279例NHL患者中，共识别出1870个DRPs（平均每位患者6.7个）。79.6%的患者为晚期疾病，63.4%的患者接受含利妥昔单抗的方案。R-CHOP方案是最常用的方案，占所有DRPs的52.7%。最常见的DRPs涉及给药问题，包括药物剂量过低（26.5%）和剂量计算错误或缺失（13.1%）。DDIs占已识别DRPs总数的13%，大多数分类为轻度相互作用。多变量回归分析确定合并症、淋巴瘤亚型和化疗周期数是DRP发生的重要预测因素。
也门的NHL患者中发现大量DRPs，平均每位患者6.7个，主要原因是给药问题。整合临床药学服务、基于指南的处方和系统的用药审查对于最大限度减少DRPs和改善治疗结果至关重要。
